Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.305 EUR -0.97% Market Closed
Market Cap: 32.7m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Wall Street
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.364 EUR
19% Upside
Average
Price Target
0.388 EUR
27% Upside
Highest
Price Target
0.42 EUR
38% Upside
Gensight Biologics SA Competitors:
Price Targets
DSGN
Design Therapeutics Inc
3% Upside
TVTX
Travere Therapeutics Inc
17% Upside
9926
Akeso Inc
1% Upside
FHTX
Foghorn Therapeutics Inc.
84% Upside
CMPS
Compass Pathways PLC
672% Upside
AELIS
Aelis Farma SA
413% Upside
ORGO
Organogenesis Holdings Inc
29% Upside
PROB
Probi AB
22% Downside

Revenue
Forecast

Revenue Estimate
Gensight Biologics SA

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 32%.

N/A
Past Growth
32%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SIGHT's stock price target?
Price Target
0.388 EUR

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.

What is Gensight Biologics SA's Revenue forecast?
Projected CAGR
32%

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 32%.

Back to Top